Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
To compare the efficacy and toxicities of pemetrexed plus platinum with other platinum regimens in patients with previously untreated advanced non-small cell lung cancer (NSCLC).A meta-analysis was performed using trials identified through PubMed, EMBASE, and Cochrane databases. Two investigators in...
Main Authors: | Ming Li, Qian Zhang, Peifang Fu, Ping Li, Aimei Peng, Guoliang Zhang, Xiaolian Song, Min Tan, Xuan Li, Yang Liu, Yueping Wu, Suyun Fan, Changhui Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3355109?pdf=render |
Similar Items
-
A meta-analysis of Pemetrexed plus Platinum Chemotherapy versus Gemcitabine plus Platinum Chemotherapy for Advanced Non-small Cell Lung Cancer
by: Jin JIANG, et al.
Published: (2011-01-01) -
Statins and the risk of lung cancer: a meta-analysis.
by: Min Tan, et al.
Published: (2013-01-01) -
Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis
by: Xiao HQ, et al.
Published: (2016-03-01) -
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.
by: Lin Wang, et al.
Published: (2017-01-01) -
Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer
by: Chung-Yu Chen, et al.
Published: (2020-10-01)